NextPharma

NextPharma

Paris, France· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

NextPharma is a Paris-based, private CDMO that has grown organically and through acquisitions since its founding in 2003. It offers a comprehensive suite of services including pharmaceutical development, clinical trial supply services, commercial manufacturing, and analytical services for both pharmaceuticals and nutritional supplements. The company is strategically positioning itself as a leading European pure-play CDMO, as evidenced by its recent divestiture of its logistics arm to sharpen this focus. Under new CEO Ajeeth Enjeti, NextPharma aims to leverage its customer-centric values and operational agility to drive sustainable growth.

Drug Delivery

Technology Platform

Integrated CDMO services platform encompassing pharmaceutical development, clinical trial manufacturing/packaging, commercial manufacturing, and analytical services for pharmaceuticals and health & nutrition products.

Opportunities

Capitalizing on the trend of pharma outsourcing and the strategic desire for European supply chain resilience to become a leading pure-play CDMO in the region.
The growing health & nutrition market provides a diversified, high-volume revenue stream alongside core pharma services.

Risk Factors

Operational risk from reliance on key client contracts and potential for quality/compliance failures.
Intense competition in the global CDMO market creates pricing pressure.
Execution risk associated with integrating acquisitions to fuel growth.

Competitive Landscape

Operates in the highly competitive global CDMO market, competing against large players like Lonza, Catalent, and Thermo Fisher Scientific, as well as many regional and niche specialists. Its strategy to be a leading European pure-play CDMO differentiates it from diversified conglomerates and logistics-heavy service providers.